Identification of G-protein coupled receptor kinase 2 in paired helical filaments and neurofibrillary tangles

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 12, 2006, Pages 1157-1169

  Takahashi, Makio ^a,b   Uchikado, Hirotake ^b   Caprotti, Domenico ^a   Weidenheim, Karen M ^c   Dickson, Dennis W ^b   Ksiezak Reding, Hanna ^a   Pasinetti, Giulio M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Corticobasal degeneration; Lewy body disease; Pick disease; Progressive supranuclear palsy; Tau

Indexed keywords

G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 5; PROTEIN KINASE B; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DIFFUSE LEWY BODY DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; NEUROFIBRILLARY TANGLE; PAIRED HELICAL FILAMENT; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; BETA-ADRENERGIC RECEPTOR KINASE; BRAIN; FEMALE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MALE; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; NEUROGLIA; NEURONS; PHOSPHORYLATION; PICK DISEASE OF THE BRAIN; PROTEIN-SERINE-THREONINE KINASES; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 33845372239     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000248542.82681.12     Document Type: Article

References (58)

1. Pao CS, Benovic JL. Phosphorylation-independent desensitization of G protein-coupled receptors? Sci STKE 2002;2002:PE42
2. Penn RB, Pronin AN, Benovic JL. Regulation of G protein-coupled receptor kinases. Trends Cardiovasc Med 2000;10:81-89
3. Doronin S, Shumay E, Wang HY, et al. Akt mediates sequestration of the beta(2)-adrenergic receptor in response to insulin. J Biol Chem 2002;277:15124-31
4. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem 1998;67:653-92
5. Penela P, Ribas C, Mayor F Jr. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 2003;15:973-81
6. Ohguro H, Rudnicka-Nawrot M, Buczylko J, et al. Structural and enzymatic aspects of rhodopsin phosphorylation. J Biol Chem 1996;271:5215-24
7. Fredericks ZL, Pitcher JA, Lefkowitz RJ. Identification of the G protein-coupled receptor kinase phosphorylation sites in the human beta2-adrenergic receptor. J Biol Chem 1996;271:13796-803
8. Pronin AN, Morris AJ, Surguchov A, et al. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 2000;275:26515-22
9. Yoshida N, Haga K, Haga T. Identification of sites of phosphorylation by G-protein-coupled receptor kinase 2 in beta-tubulin. Eur J Biochem 2003;270:1154-63
10. Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-84
11. Dickson DW, Liu W, Hardy J, et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999;155:1241-51
12. Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-64
13. Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 2003;62:644-54
14. Okochi M, Walter J, Koyama A, et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 2000;275:390-97
15. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8:657-63
16. Delacourte A, Sergeant N, Wattez A, et al. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 1998;43:193-204
17. Popescu A, Lippa CF, Lee VM, et al. Lewy bodies in the amygdala: Increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 2004;61:1915-19
18. Kotzbauer PT, Trojanowsk JQ, Lee VM. Lewy body pathology in Alzheimer's disease. J Mol Neurosci 2001;17:225-32
19. Iseki E, Togo T, Suzuki K, et al. Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol (Berl) 2003;105:265-70
20. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: Common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 2004;27:129-34
21. Arima K, Hirai S, Sunohara N, et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res 1999;843:53-61
22. Ishizawa T, Mattila P, Davies P, et al. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003;62:389-97
23. Mori H, Oda M, Komori T, et al. Lewy bodies in progressive supranuclear palsy. Acta Neuropathol (Berl) 2002;104:273-78
24. Takeda A, Hashimoto M, Mallory M, et al. C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol (Berl) 2000;99:296-304
25. Mori F, Hayashi S, Yamagishi S, et al. Alpha- and beta-synuclein- immunoreactive Pick bodies in the dentate gyrus. Acta Neuropathol (Berl) 2002;104:455-61
26. Pei JJ, Khatoon S, An WL, et al. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol (Berl) 2003;105:381-92
27. Griffin RJ, Moloney A, Kelliher M, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 2005;93:105-17
28. Ksiezak-Reding H, Pyo HK, Feinstein B, et al. Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochim Biophys Acta 2003;1639:159-68
29. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
30. Weiner MF, Risser RC, Cullum CM, et al. Alzheimer's disease and its Lewy body variant: A clinical analysis of postmortem verified cases. Am J Psychiatry 1996;153:1269-73
31. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005;65:1863-72
32. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59
33. Takahashi M, Weidenheim KM, Dickson DW, et al. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J Neuropathol Exp Neurol 2002;61:33-45
34. Ksiezak-Reding H, Yang G, Simon M, et al. Assembled tau filaments differ from native paired helical filaments as determined by scanning transmission electron microscopy (STEM). Brain Res 1998;814:86-98
35. Gordon-Krajcer W, Yang L, Ksiezak-Reding H. Conformation of paired helical filaments blocks dephosphorylation of epitopes shared with fetal tau except Ser199/202 and Ser202/Thr205. Brain Res 2000;856:163-75
36. Ishizawa K, Ksiezak-Reding H, Davies P, et al. A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease. Acta Neuropathol (Berl) 2000;100:235-44
37. Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 1999;47:719-30
38. Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999;246(suppl 2):II6-15
39. Feany MB, Dickson DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995;146:1388-96
40. Ksiezak-Reding H, Wall JS. Mass and physical dimensions of two distinct populations of paired helical filaments. Neurobiol Aging 1994;15:11-19
41. Arriza JL, Dawson TM, Simerly RB, et al. The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain. J Neurosci 1992;12:4045-55
42. Erdtmann-Vourliotis M, Mayer P, Ammon S, et al. Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res 2001;95:129-37
43. Lombardi MS, van den Tweel E, Kavelaars A, et al. Hypoxia/ischemia modulates G protein-coupled receptor kinase 2 and beta-arrestin-1 levels in the neonatal rat brain. Stroke 2004;35:981-86
44. Grange-Midroit M, Garcia-Sevilla JA, Ferrer-Alcon M, et al. G protein-coupled receptor kinases, beta-arrestin-2 and associated regulatory proteins in the human brain: Postmortem changes, effect of age and subcellular distribution. Brain Res Mol Brain Res 2002;101:39-51
45. Cullen KM, Halliday GM, Cartwright H, et al. Improved selectivity and sensitivity in the visualization of neurofibrillary tangles, plaques and neuropil threads. Neurodegeneration 1996;5:177-87
46. Togo T, Akiyama H, Iseki E, et al. Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions. Acta Neuropathol (Berl) 2004;107:504-508
47. Suo Z, Wu M, Citron BA, et al. Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: An association with early beta-amyloid accumulation. J Neurosci 2004;24:3444-52
48. Puig B, Ferrer I, Luduena RF, et al. BetaII-tubulin and phospho-tau aggregates in Alzheimer's disease and Pick's disease. J Alzheimers Dis 2005;7:213-20
49. Pitcher JA, Hall RA, Daaka Y, et al. The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin. J Biol Chem 1998;273:12316-24
50. Murga C, Fukuhara S, Gutkind JS. A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt. J Biol Chem 2000;275:12069-73
51. Kyoung Pyo H, Lovati E, Pasinetti GM, et al. Phosphorylation of tau at THR212 and SER214 in human neuronal and glial cultures: The role of AKT. Neuroscience 2004;127:649-58
52. Ishizawa T, Sahara N, Ishiguro K, et al. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol 2003;163:1057-67
53. Reynolds CH, Betts JC, Blackstock WP, et al. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 2000;74:1587-95
54. Lee G, Thangavel R, Sharma VM, et al. Phosphorylation of tau by fyn: Implications for Alzheimer's disease. J Neurosci 2004;24:2304-12
55. Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci U S A 1998;95:9914-19
56. Pronin AN, Carman CV, Benovic JL. Structure-function analysis of G protein-coupled receptor kinase-5. Role of the carboxyl terminus in kinase regulation. J Biol Chem 1998;273:31510-18
57. Otvos L Jr, Feiner L, Lang E, et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994;39:669-73
58. Carmel G, Mager EM, Binder LI, et al. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem 1996;271:32789-95